

Allergies: _____

Diagnosis: _____ Status: Inpatient Observation SDC

Admit to: Interventional Unit Progressive Cardiac Care Critical Care

Heart Failure: (Check box to activate)
ECG X 1. Restrict fluids to 1200 mL/ day
 Pro-brain natriuretic peptide (BNP) Troponin I
 Echocardiogram

Chest Pain/ AMI: (Check box to activate)
Cardiac markers (ROMI) on arrival to unit, at 1 & 4 hours
ECG on arrival to unit, daily, and PRN chest pain

NURSING INTERVENTIONS: (Check box/ fill in to activate)

Vital Signs every 4 hours and PRN
Cardiac monitor
O₂ 0 - 6 L for chest pain and/ or to keep O₂ sat greater than or equal to 92%
Weigh daily
I&O
Document smoking cessation teaching if patient has smoked within 1 year physician, check if already done

Activity:

- Activity as tolerated
- Bed rest with bathroom privileges
- Complete bed rest with SCDs

Notify physician if:

SBP less than _____ or greater than _____ mmHg
O₂ greater than 6L required
Unrelieved chest pain

DIETARY: (Check box/ fill in to activate)

- Cardiac diet as tolerated
- NPO

Other: _____

IV THERAPY: (Fill in to activate)

Saline lock or:
IV Fluid: _____ to infuse at _____ mL/ hour

LABORATORY/ DIAGNOSTICS: if not done in ED (Check box/ fill in to activate)

- Chest X-Ray AP and Lateral Reason: _____
- Chest X-Ray portable AP Reason: _____
- CBC Basic Metabolic Panel Magnesium Digoxin level PT/ INR TSH Lipid Profile 8 hour fasting

CONSULTS: (Check box to activate)

Nutrition Consult/ Patient Education Review
 Cardiac Rehab referral

Physician Signature

Date

Time

dalteparin (FRAGMIN) dose rounding table
For use in conditions other than UA, non-Q wave MI

Patient Weight (lbs)	Patient Weight (kg)	Dalteparin dose 200 units/ kg subcutaneously once daily
less than 125	Less than 57	10,000 units
125 - 150	57 - 68	12,500 units
151 - 181	69 - 82	15,000 units
182 - 216	83 - 98	18,000 units
217 - 254	99 - 115	22,500 units
255 - 294	116 - 134	25,000 units
295 - 330	135 - 150	28,000 units
331 - 372	151 - 169	30,000 units
373 - 418	170 - 190	36,000 units

Approved by Pharmacy & Therapeutics Committee March 2010